Related Experiment Video
Updated: Apr 26, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Dose-escalated radiation therapy with and without short-course androgen deprivation for intermediate-risk prostate
David Schreiber1, Justin Rineer2, Aparna Surapaneni3
1Department of Veterans Affairs, New York Harbor Healthcare System, Brooklyn, New York, NY, U.S.A. Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn, NY, U.S.A. David.schreiber@va.gov.
Aim:
To investigate outcomes in intermediate-risk (IR) prostate cancer patients receiving dose-escalated external beam radiation therapy (RT) with or without short-course androgen deprivation (ADT).
Patients And Methods:
This study comprised of 203 patients with IR prostate cancer who were treated at a single institution to a dose of 7,560 cGy or more between 2003-2010. Of these, 62 (30.5%) patients received ADT. Biochemical recurrence, distant metastatic-free survival, prostate cancer-specific survival, and overall survival were analyzed using the Kaplan-Meier method.
Results:
The median follow-up was 62 months and the median duration of ADT was 6 months. The 6-year biochemical control was 89.2% for those receiving RT plus ADT versus 76.7% in those receiving RT alone (p=0.02). There were no differences between the two groups regarding distant metastatic-free survival, prostate cancer-specific survival, and overall survival (respective p-values of 0.91, 0.50, 0.67).
Conclusion:
Dose-escalated RT and short-course ADT results in improved biochemical outcomes for IR prostate cancer.
